Considering that IL‐17 is an initiator of the early inflammatory response, which has been shown to play an essential role in the development of inflammatory bowel disease, asthma, and tuberculosis [6, 7], we believe that IL‐17 also participates in the pathogenesis and development of CTEPH, which warrants further studies. Here, IL17A is linked to chronic thromboembolic pulmonary hypertension.